GlassScriptPhysician profile
Ghosn A Issa
NPI 1215975198
$1,086.61
in general payments reported to CMS, 2019-2025
17 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2022: $108 · 2023: $193 · 2024: $150 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518 · Education: $48.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.58 |
| Education | $48.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $264.10 | 2022-2025 | Minimed 780g |
| Dexcom, INC. | $113.54 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $86.92 | 2023-2025 | Freestyle Libre 3 |
| Eisai INC. | $78.98 | 2019 | |
| Lilly USA, LLC | $78.38 | 2019-2024 | Jardiance, Mounjaro |
| Radius Health, INC. | $78.34 | 2019 | |
| Novo Nordisk INC | $74.43 | 2019-2025 | Ozempic |
| Amgen INC. | $67.36 | 2019-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $58.67 | 2019 | |
| Neurocrine Biosciences, INC. | $48.08 | 2025 | |
| Insulet Corporation | $31.09 | 2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $26.13 | 2019-2024 | |
| Shire North American Group INC | $20.84 | 2019 | |
| Abbvie INC. | $20.63 | 2019 | |
| Tandem Diabetes Care, INC. | $13.91 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.10 | 2019 | |
| Merck Sharp & Dohme LLC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghosn Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.